155 related articles for article (PubMed ID: 33539971)
1. Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
Steuer CE; Jegede OA; Dahlberg SE; Wakelee HA; Keller SM; Tester WJ; Gandara DR; Graziano SL; Adjei AA; Butts CA; Ramalingam SS; Schiller JH;
J Thorac Oncol; 2021 Jun; 16(6):960-967. PubMed ID: 33539971
[TBL] [Abstract][Full Text] [Related]
2. Prediagnosis Smoking Cessation and Overall Survival Among Patients With Non-Small Cell Lung Cancer.
Wang X; Romero-Gutierrez CW; Kothari J; Shafer A; Li Y; Christiani DC
JAMA Netw Open; 2023 May; 6(5):e2311966. PubMed ID: 37145597
[TBL] [Abstract][Full Text] [Related]
3. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Pensieri MV; Russano M; Cantini L; Nigro O; Leonetti A; Bordi P; Minuti G; Landi L; De Toma A; Donisi C; Ricciardi S; Migliorino MR; Napoli VM; Leone G; Metro G; Banna GL; Friedlaender A; Addeo A; Ficorella C; Porzio G
Thorac Cancer; 2021 Mar; 12(6):880-889. PubMed ID: 33527756
[TBL] [Abstract][Full Text] [Related]
4. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer.
Tsao AS; Liu D; Lee JJ; Spitz M; Hong WK
Cancer; 2006 Jun; 106(11):2428-36. PubMed ID: 16634096
[TBL] [Abstract][Full Text] [Related]
5. Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
Popat S; Liu SV; Scheuer N; Gupta A; Hsu GG; Ramagopalan SV; Griesinger F; Subbiah V
JAMA Netw Open; 2022 May; 5(5):e2214046. PubMed ID: 35612853
[TBL] [Abstract][Full Text] [Related]
6. Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.
Reck M; Blais N; Juhasz E; Gorbunova V; Jones CM; Urban L; Orlov S; Barlesi F; Kio E; Keilholz U; Qin Q; Qian J; Nickner C; Dziubinski J; Xiong H; Mittapalli RK; Dunbar M; Ansell P; He L; McKee M; Giranda V; Ramalingam SS
J Thorac Oncol; 2017 Jul; 12(7):1098-1108. PubMed ID: 28461256
[TBL] [Abstract][Full Text] [Related]
7. Impact of current versus former smoking status on the outcomes of non-metastatic non-small cell lung cancer treated with upfront surgery; findings from the National Lung Screening Trial.
Abdel-Rahman O
Expert Rev Respir Med; 2019 Jun; 13(6):585-591. PubMed ID: 31055993
[No Abstract] [Full Text] [Related]
8. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
[TBL] [Abstract][Full Text] [Related]
9. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer.
Weiss JM; Villaruz LC; O'Brien J; Ivanova A; Lee C; Olson JG; Pollack G; Gorman R; Socinski MA; Stinchombe TE
Clin Lung Cancer; 2016 Mar; 17(2):128-32. PubMed ID: 26774201
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathological and survival differences between never and ever smokers with non-small cell lung cancer.
Muallaoglu S; Karadeniz C; Mertsoylu H; Ayberk Besen A; Sezer A; Murat Sedef A; Kose F; Ozyilkan O
J BUON; 2014; 19(2):453-8. PubMed ID: 24965406
[TBL] [Abstract][Full Text] [Related]
11. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients.
Zhou W; Heist RS; Liu G; Park S; Neuberg DS; Asomaning K; Wain JC; Lynch TJ; Christiani DC
Lung Cancer; 2006 Sep; 53(3):375-80. PubMed ID: 16814423
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC.
Varlotto JM; Wang Y; Sun Z; Wakelee HA; Ramalingam S; Schiller J
JTO Clin Res Rep; 2022 Mar; 3(3):100274. PubMed ID: 35281954
[TBL] [Abstract][Full Text] [Related]
13. Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality : A Prospective Cohort Study.
Sheikh M; Mukeriya A; Shangina O; Brennan P; Zaridze D
Ann Intern Med; 2021 Sep; 174(9):1232-1239. PubMed ID: 34310171
[TBL] [Abstract][Full Text] [Related]
14. The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer.
Wallace ND; Alexander M; Xie J; Ball D; Hegi-Johnson F; Plumridge N; Siva S; Shaw M; Harden S; John T; Solomon B; Officer A; MacManus M
Lung Cancer; 2024 Apr; 190():107531. PubMed ID: 38513538
[TBL] [Abstract][Full Text] [Related]
15. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
[TBL] [Abstract][Full Text] [Related]
16. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal study to assess impact of smoking at diagnosis and quitting on 1-year survival for people with non-small cell lung cancer.
Gemine RE; Ghosal R; Collier G; Parry D; Campbell I; Davies G; Davies K; Lewis KE;
Lung Cancer; 2019 Mar; 129():1-7. PubMed ID: 30797485
[TBL] [Abstract][Full Text] [Related]
18. Smoking status and survival in the national comprehensive cancer network non-small cell lung cancer cohort.
Ferketich AK; Niland JC; Mamet R; Zornosa C; D'Amico TA; Ettinger DS; Kalemkerian GP; Pisters KM; Reid ME; Otterson GA
Cancer; 2013 Feb; 119(4):847-53. PubMed ID: 23023590
[TBL] [Abstract][Full Text] [Related]
19. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
20. Does Quitting Smoking Make a Difference Among Newly Diagnosed Head and Neck Cancer Patients?
Choi SH; Terrell JE; Bradford CR; Ghanem T; Spector ME; Wolf GT; Lipkus IM; Duffy SA
Nicotine Tob Res; 2016 Dec; 18(12):2216-2224. PubMed ID: 27613928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
